Document ID: chunk:federal_register_of_legislation:F2025C00183:clause:1_71175
Version: federal_register_of_legislation:F2025C00183
Segment Type: clause
Provision Reference: sch 1 cl 71175
Character Range: 231371–232990

71175                A test, requested by a specialist or consultant physician, to diagnose neuromyelitis optica spectrum disorder (NMOSD) or myelin oligodendrocyte glycoprotein antibody‑related demyelination (MARD), by the detection of one or more antibodies, for a patient:                                                                                                                                                                                                                                 50.00
                     (a) suspected of having NMOSD or MARD; and
                     (b) with any of the following:
                     (i) recurrent, bilateral or severe optic neuritis;
                     (ii) recurrent longitudinal extensive transverse myelitis (LETM);
                     (iii) area postrema syndrome (unexplained hiccups, nausea or vomiting);
                     (iv) acute brainstem syndrome;
                     (v) symptomatic narcolepsy or acute diencephalic clinical syndrome with typical NMOSD magnetic resonance imaging lesions;
                     (vi) symptomatic cerebral syndrome with typical NMOSD magnetic resonance imaging lesions;
                     (vii) monophasic neuromyelitis optica (no recurrence, and simultaneous or closely related optic neuritis and LETM within 30 days of each other);
                     (viii) acute disseminated encephalomyelitis;
                     (ix) aseptic meningitis and encephalomyelitis;
                     (x) poor recovery from multiple sclerosis relapses
                     Applicable not more than 4 times in 12 months